Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1156405 | 0.99 | PLAU (0.41) | PLAUCYP19A1RAPGEF4HTR6ALDH1A1 | |
| SCHEMBL1763296 | 0.88 | ALDH1A1 (0.51) | CYP19A1RAPGEF4HTR6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1156314 | 0.87 | ALDH1A1 (0.50) | CYP19A1RAPGEF4HTR6ALDH1A1MAPT | |
| SCHEMBL1580431 | 0.84 | LMNA (0.43) | CYP19A1RAPGEF4HTR6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1156502 | 0.83 | LMNA (0.42) | CYP19A1RAPGEF4HTR6ALDH1A1MAPT | |
| SCHEMBL1580844 | 0.82 | CYP11B1 (0.46) | CYP19A1ALDH1A1KMT2A | |
| SCHEMBL1580931 | 0.82 | ALDH1A1 (0.45) | RAPGEF4HTR6ALDH1A1MAPTMEN1 | |
| SCHEMBL1156820 | 0.82 | EGFR (0.44) | HTR6ALDH1A1MAPTKMT2A | |
| SCHEMBL30427580 | 0.82 | ALDH1A1 (0.43) | CYP19A1RAPGEF4HTR6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1157160 | 0.82 | CYP11B1 (0.45) | CYP19A1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | PLAU 1110/4885CYP19A1 50/4885RAPGEF4 4027/4885 |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | PLAU 1110/4885CYP19A1 50/4885RAPGEF4 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.